{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:11:01Z","timestamp":1791555061288,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000},"content-version":"vor","delay-in-days":289,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jlr.org"],"crossmark-restriction":true},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1194\/jlr.p094763","type":"journal-article","created":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T20:45:28Z","timestamp":1569357928000},"page":"2082-2089","update-policy":"https:\/\/doi.org\/10.1194\/jlr.f110.005975","source":"Crossref","is-referenced-by-count":71,"title":["Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis"],"prefix":"10.1016","volume":"60","author":[{"given":"Michael B.","family":"Boffa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya T.","family":"Marar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"Yeang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Viney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuting","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Witztum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlys L.","family":"Koschinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1194\/jlr.P094763_bib1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.P094763_bib2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.P094763_bib3","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein(a) and lipoprotein(a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.P094763_bib4","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1194\/jlr.M060210","article-title":"Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a)","volume":"56","author":"Scipione","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.P094763_bib5","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation."},{"key":"10.1194\/jlr.P094763_bib6","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.P094763_bib7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/01.ATV.10.2.240","article-title":"Lipoprotein(a), fibrin binding, and plasminogen activation","volume":"10","author":"Loscalzo","year":"1990","journal-title":"Arteriosclerosis."},{"key":"10.1194\/jlr.P094763_bib8","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/01.ATV.11.3.629","article-title":"Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu","volume":"11","author":"Rouy","year":"1991","journal-title":"Arterioscler. Thromb."},{"key":"10.1194\/jlr.P094763_bib9","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood.V82.2.392.392","article-title":"Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?","volume":"82","author":"Hervio","year":"1993","journal-title":"Blood."},{"key":"10.1194\/jlr.P094763_bib10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nm0395-256","article-title":"Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis","volume":"1","author":"Palabrica","year":"1995","journal-title":"Nat. Med."},{"key":"10.1194\/jlr.P094763_bib11","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1021\/bi00015a028","article-title":"Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation","volume":"34","author":"Sangrar","year":"1995","journal-title":"Biochemistry."},{"key":"10.1194\/jlr.P094763_bib12","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1161\/01.CIR.96.5.1612","article-title":"Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo","volume":"96","author":"Biemond","year":"1997","journal-title":"Circulation."},{"key":"10.1194\/jlr.P094763_bib13","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jacc.2012.01.078","article-title":"Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism","volume":"60","author":"Helgadottir","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.P094763_bib14","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/ATVBAHA.112.248765","article-title":"Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis","volume":"32","author":"Kamstrup","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.P094763_bib15","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3324\/haematol.2012.073833","article-title":"Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children","volume":"98","author":"Goldenberg","year":"2013","journal-title":"Haematologica."},{"key":"10.1194\/jlr.P094763_bib16","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1161\/01.ATV.20.2.493","article-title":"Homocysteine and lipoprotein(a) interact to increase CAD risk in young men and women","volume":"20","author":"Foody","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.P094763_bib17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/CIRCRESAHA.118.313864","article-title":"Potential causality and emerging medical therapies for lipoprotein(a) and its associated oxidized phospholipids in calcific aortic valve stenosis","volume":"124","author":"Tsimikas","year":"2019","journal-title":"Circ. Res."},{"key":"10.1194\/jlr.P094763_bib18","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet."},{"key":"10.1194\/jlr.P094763_bib19","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet."},{"key":"10.1194\/jlr.P094763_bib20","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jacl.2017.08.005","article-title":"Niacin and heart disease prevention: engraving its tombstone is a mistake","volume":"11","author":"Superko","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"10.1194\/jlr.P094763_bib21","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1093\/eurheartj\/ehy862","article-title":"Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin\/kexin type 9 antibody treatment","volume":"40","author":"Stiekema","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1194\/jlr.P094763_bib22","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.jacc.2011.12.033","article-title":"Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction","volume":"59","author":"Leibundgut","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.P094763_bib23","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/CIRCULATIONAHA.115.016757","article-title":"Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve","volume":"132","author":"Bouchareb","year":"2015","journal-title":"Circulation."},{"key":"10.1194\/jlr.P094763_bib24","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/j.1538-7836.2008.03183.x","article-title":"Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation","volume":"6","author":"Feric","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1194\/jlr.P094763_bib25","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","article-title":"Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States","volume":"36","author":"Varvel","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.P094763_bib26","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1161\/01.ATV.18.9.1393","article-title":"Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN","volume":"18","author":"Rand","year":"1998","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.P094763_bib27","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood.V98.10.2980","article-title":"Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis","volume":"98","author":"Caplice","year":"2001","journal-title":"Blood."},{"key":"10.1194\/jlr.P094763_bib28","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.thromres.2014.01.024","article-title":"Lipoprotein (a), LPA Ile4399Met, and fibrin clot properties","volume":"133","author":"Rowland","year":"2014","journal-title":"Thromb. Res."},{"key":"10.1194\/jlr.P094763_bib29","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3945\/ajcn.115.124321","article-title":"Lipid biomarkers and long-term risk of cancer in the Women's Health Study","volume":"103","author":"Chandler","year":"2016","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1194\/jlr.P094763_bib30","first-page":"92","article-title":"Fibrinolysis and lipoprotein(a) in women with coronary artery disease. Influence of hormone replacement therapy","volume":"86","author":"Falc\u00f3","year":"2001","journal-title":"Haematologica."},{"key":"10.1194\/jlr.P094763_bib31","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1016\/j.thromres.2012.06.005","article-title":"Altered fibrin clot properties are associated with residual vein obstruction: effects of lipoprotein(a) and apolipoprotein(a) isoform","volume":"130","author":"Undas","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1194\/jlr.P094763_bib32","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/j.1538-7836.2007.02637.x","article-title":"Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a) and homocysteine","volume":"5","author":"Undas","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1194\/jlr.P094763_bib33","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1038\/srep05318","article-title":"Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo","volume":"4","author":"M\u00e5nsson","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1194\/jlr.P094763_bib34","doi-asserted-by":"crossref","first-page":"52841","DOI":"10.1074\/jbc.M310425200","article-title":"Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a)","volume":"278","author":"Edelstein","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.P094763_bib35","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1194\/jlr.P027235","article-title":"Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia","volume":"53","author":"Arai","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.P094763_bib36","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1399-0004.1997.tb04358.x","article-title":"High plasma levels of apo(a) fragments in Caucasians and African-Americans with end-stage renal disease: implications for plasma Lp(a) assay","volume":"52","author":"Mooser","year":"1997","journal-title":"Clin. Genet."},{"key":"10.1194\/jlr.P094763_bib37","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet."},{"key":"10.1194\/jlr.P094763_bib38","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2010.10.052","article-title":"Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice","volume":"57","author":"Merki","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.P094763_bib39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/MOL.0000000000000171","article-title":"\u2018LDL-C\u2019 = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin\/kexin type 9 era of potent LDL-C lowering","volume":"26","author":"Yeang","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1194\/jlr.P094763_bib40","doi-asserted-by":"crossref","first-page":"23260","DOI":"10.1074\/jbc.M302780200","article-title":"Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces","volume":"278","author":"Hancock","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.P094763_bib41","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1067\/mva.2000.107757","article-title":"Apolipoprotein (a) fragments in relation to human carotid plaque instability","volume":"32","author":"Fortunato","year":"2000","journal-title":"J. Vasc. Surg."},{"key":"10.1194\/jlr.P094763_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/s41569-018-0153-2","article-title":"Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease","author":"Boffa","year":"2019","journal-title":"Nat. Rev. Cardiol."}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227520310464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227520310464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1194\/jlr.P094763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T10:34:08Z","timestamp":1637404448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022227520310464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0022227520310464"],"URL":"https:\/\/doi.org\/10.1194\/jlr.p094763","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}